Interventional Oncology Market Worth $2.9 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
CHICAGO, March 13, 2019 /PRNewswire/ -- According to the new market research report "Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024", published by MarketsandMarkets(TM), the Interventional Oncology Market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8%.
https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
Don't miss out on business opportunities in Interventional Oncology Market
Rising preference for minimally invasive procedures, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research are some of the major factors driving the growth of this market.
The TARE/SIRT segment accounted for the largest share of the Interventional Oncology Market, by procedure, in 2018
Based on procedure, the Interventional Oncology Market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2018, the TARE/SIRT procedures segment accounted for the largest market share majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures).
Browse and in-depth TOC on "Interventional Oncology Market"
140 - Tables
33 - Figures
180 - Pages
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=203687164
Liver cancer segment to register the highest CAGR in the Interventional Oncology Market, by application, during the forecast period
Based on cancer type, the Interventional Oncology Market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). Growth in this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology.
North America accounted for the largest share of the Interventional Oncology Market in 2018
The Interventional Oncology Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the Interventional Oncology Market owing to factors such as the rising incidence of cancer, easy accessibility to interventional oncology, and the high adoption of technological advancements (owing to the significant per capita annual healthcare expenditure by the US government).
Inquiry Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=203687164
The major players operating in the Interventional Oncology Market are Medtronic (Ireland), Boston Scientific (US), BTG plc (UK), Merit Medical Systems (US), and Terumo (Japan). The other prominent players operating in the overall Interventional Oncology Market include AngioDynamics (US), Ethicon (part of J&J) (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), and Interface Biomaterials BV (Netherlands).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
About MarketsandMarkets(TM)
MarketsandMarkets(TM) provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets(TM) for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets(TM) are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets(TM) now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets(TM) is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets(TM) INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/interventional-oncology-market.asp
Visit Our Website: https://www.marketsandmarkets.com
View original content:http://www.prnewswire.com/news-releases/interventional-oncology-market-worth-2-9-billion-by-2024--exclusive-report-by-marketsandmarkets-300811646.html
SOURCE MarketsandMarkets
